Clinical trial
Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related…
NCT00088192 · Eyetech Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00088192 |
|---|---|
| Title | Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD) |
| Official title | An Open Label, Non-Comparative Protocol for Use of Intravitreous Pegaptanib Sodium Injection Every 6 Weeks in Patients With Exudative Age-Related Macular Degeneration (AMD) |
| Lead sponsor | Eyetech Pharmaceuticals, Industry |
| Collaborators | Pfizer Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | Macular Degeneration |
| Intervention type | Drug |
| Interventions | pegaptanib sodium |
| Start date | Jul 1, 2004 |
| First posted | Jul 22, 2004 |
| Last update posted | Aug 30, 2005 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: